Pharmacokinetic properties of different formulations of botulinum neurotoxin type A

Jankovic, 1991, N Engl J Med, 324, 1186, 10.1056/NEJM199104253241707

Brin, 1997, Eur J Neurol, 42, 59

Durif, 1995, Eur J Neurol, 2, 17

Hambleton, 1994, J R Soc Med, 87, 719

Schantz, 1990, Lancet, 17, 421, 10.1016/0140-6736(90)90263-5

Quinn, 1989, Lancet, 1, 964, 10.1016/S0140-6736(89)92551-8

Borodic, 1996, Neurology, 46, 26, 10.1212/WNL.46.1.26

Dressler, 1997, Eur J Neurol, 42, 67

Preparation and characterization of botulinum toxin type A for human treatment. In: editors. Therapy with botulinum toxin. New York: Marcel Decker; 1994. p 41-49.

Bülbring, 1946, Br J Pharmacol, 1, 38

Sloop, 1996, Neurology, 46, 1382, 10.1212/WNL.46.5.1382

Wohlfarth, 1997, Arch Pharmacol, 355, 335, 10.1007/PL00004951

Goodnough, 1992, Appl Environ Microbiol, 58, 3426, 10.1128/AEM.58.10.3426-3428.1992